« Previous Next » Health Outcomes Research in Medicine
Volume 3, Issue 1 , Pages e37-e44 , February 2012

Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature

Paul E. Stang, PhD
- Johnson & Johnson Pharmaceutical Research and Development LLC, Titusville, NJ
- Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD
- Corresponding Author: Paul E. Stang, PhD, Johnson & Johnson, 1125 Trenton-Harbourton Road, PO Box 200, MS K304, Titusville, NJ 08560.
Patrick B. Ryan, PhD
- Johnson & Johnson Pharmaceutical Research and Development LLC, Titusville, NJ
- Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD
Stacie B. Dusetzina, PhD
- Department of Health Care Policy, Harvard Medical School, Boston, Mass
Abraham G. Hartzema, PharmD, MSPH, PhD
- Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD
- College of Pharmacy, University of Florida, Gainesville
- At the time of this work Dr Hartzema was on sabbatical with the Office of Critical Path Programs at the US Food and Drug Administration, Silver Spring, MD.
Christian Reich, MD, PhD
- Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD
J. Marc Overhage, MD, PhD
- Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD
- Siemens Health Services, Malvern, PA
Judith A. Racoosin, MD, MPH
- Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

Title	About	Type	File Size
Appendix 1			0 MB
Appendix 2			0 MB

Please note that add-on components may require plug-in applications.

This article expresses the views of the authors and does not necessarily represent those of their affiliated organizations. We gratefully acknowledge the work of RTI and UBC in the generation of the evidence tables used in this manuscript. Their work was funded via contracts from the Foundation for the National Institutes of Health.

The Observational Medical Outcomes Partnership is funded by the Foundation for the National Institutes of Health through generous contributions from the following: Abbott, Amgen Inc., AstraZeneca, Bayer Healthcare Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmaceutical Research Manufacturers of America (PhRMA), Roche, sanofi-aventis, Schering-Plough Corporation, and Takeda. Patrick Ryan and Paul Stang are employees of Johnson & Johnson Pharmaceutical Research and Development. Abraham Hartzema is funded by NIH, Pfizer, and Florida AHCA. No person was compensated for the production of or editing of this manuscript.

PII: S1877-1319(11)00048-6

doi: 10.1016/j.ehrm.2011.11.003

« Previous Next » Health Outcomes Research in Medicine
Volume 3, Issue 1 , Pages e37-e44 , February 2012